Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

zotatifin (eFT226)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

eFFECTOR Therap

Drug class:

eIF4A1 inhibitor

Related drugs:

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib + eFT226 Sensitive: B - Late Trials abemaciclib + eFT226 Sensitive : B	abemaciclib + eFT226 Sensitive: B - Late Trials abemaciclib + eFT226 Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	eFT226 Sensitive: C2 – Inclusion Criteria eFT226 Sensitive : C2	eFT226 Sensitive: C2 – Inclusion Criteria eFT226 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	abemaciclib + eFT226 Sensitive: C3 – Early Trials abemaciclib + eFT226 Sensitive : C3	abemaciclib + eFT226 Sensitive: C3 – Early Trials abemaciclib + eFT226 Sensitive : C3
FGFR1 amplification	Colorectal Cancer	FGFR1 amplification	Colorectal Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR1 amplification	Non Small Cell Lung Cancer	FGFR1 amplification	Non Small Cell Lung Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 amplification	Colorectal Cancer	FGFR2 amplification	Colorectal Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 amplification	Non Small Cell Lung Cancer	FGFR2 amplification	Non Small Cell Lung Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D